1[1]Kallioniemi OP. Biochip technologies in cancer research. Ann Med,2001,33(2) :142-147.
2[2]Kononen J, Bubendorf L, Kallioniemi, A, et al.Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med, 1998,4(7):844-847.
3[3]Schraml P, Kononen J, Bubendorf L, et al. Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res. 1999,5 (8):1966-1975.
4[4]Fejzo M, Slamon D. Frozen tumor tissue microarray technology for analysis of tumor RNA, DNA, and proteins. Am J Pathol,2001,59(5): 1645-1650.
5[5]Camp R, Charette L, Rimm D. Validation of tissue microarray technology in breast carcinoma. Lab Invest, 2000,80(12): 1943-1949.
6[6]Hoos A, Cordon-Cardo C. Tissue microarray porfiling of cancer specimens and cell lines: Opportunities and limitations. Lab Invest, 2001,81(10): 1331-1338.
7[7]Meinhold-Heerlein I,Stener-Liewen F, Liewen H, et al. Expression and potential role of Fasassociated phosphatase-1 in ovarian cancer. Am J Pathol, 158(4): 1335-1344.
8[8]Bubendorf L, Kolmer M, Kononen J, et al. Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. J Natl Can Inst, 1999,91(20): 1758-1764.
9[9]Ekins R,Chu FW. Microarrays:their origins and application Trends in Biotechnol, 1999, 17 (6):217-218.
10[10]Wooster R. Cancer classification with DNA microarrays is less more? Trends Genet 2000, 16(8): 327-329.
